Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 15/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | FPR1 | P21462 | 1/20 | 0.37 |
| ▸ | FPR2 | P25090 | 1/20 | 0.37 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.37 |
| ▸ | CCKAR | P32238 | 2/20 | 0.36 |
| ▸ | CCKBR | P32239 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27057612 | 0.89 | SLC6A2 (0.39) | SCN9ASLC6A2FPR1FPR2 | |
| SCHEMBL25815779 | 0.85 | SLC6A2 (0.53) | SCN9ASLC6A2 | |
| SCHEMBL25376173 | 0.83 | TEAD1 (0.48) | SLC6A2FPR1FPR2AADATCCKAR | |
| SCHEMBL31668904 | 0.83 | TEAD1 (0.48) | SLC6A2FPR1FPR2AADATCCKAR | |
| SCHEMBL27057694 | 0.82 | SLC6A2 (0.39) | SCN9ASLC6A2FPR1FPR2 | |
| SCHEMBL30767936 | 0.82 | SLC6A2 (0.39) | SCN9ASLC6A2FPR1FPR2 | |
| SCHEMBL25815593 | 0.80 | SCN9A (0.51) | SCN9ASLC6A2 | |
| SCHEMBL30767976 | 0.79 | RORC (0.38) | SCN9AFPR1FPR2 | |
| SCHEMBL27057236 | 0.79 | RORC (0.38) | SCN9AFPR1FPR2 | |
| SCHEMBL30767958 | 0.78 | SLC6A2 (0.39) | SCN9ASLC6A2FPR2AADAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025856-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | CISTIM LEUVEN VZW (BE) | 2024-01-25 | — | — | US | disclosed |
| US-20240025856-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | CISTIM LEUVEN VZW (BE) | 2024-01-25 | — | — | US | disclosed |
| US-20230278962-A1 | Tetrahydrobenzoazepinones and Related Analogs for Inhibiting YAP/TAZ-TEAD | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-09-07 | — | — | US | disclosed |
| WO-2023122781-A2 | TETRAHYDROBENZOAZEPINONES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | THE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025856-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | YAP1, TEAD2, TEAD1 | SCN9A 3864/4885SLC6A2 4362/4885FPR1 2283/4885 |
| US-20230278962-A1 | Tetrahydrobenzoazepinones and Related Analogs for Inhibiting YAP/TAZ-TEAD | YAP1, TEAD2, TEAD4 | SCN9A 4360/4885SLC6A2 4206/4885FPR1 2737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.